hVIVO are pleased to be attending this year’s ESCMID conference. Our team are looking forward to hearing the latest research from other presenters and share our own findings and expertise.
Our Director of Clinical Science, Nicolas Noulin, will be presenting an oral abstract at this year's event. Having created and completed a characterisation study of our new hMPV virus model, Nicolas will be presenting the data from this study. The abstract, titled “Establishing a human challenge model for human metapneumovirus: disease characteristics and immune responses” detail the findings.
With a further 5 abstracts accepted at ESCMID, please continue reading to find out more.
As the global leader in human challenge trials, hVIVO has a long and unique history in infectious disease clinical research. Having moved to our new Canary Wharf facility in July 2024, we not only have the world largest quarantine facility with 50 containment level 3 bedrooms but a large virology and immunology specialist laboratory with BSL2 and BSL3 laboratory facilities. This move has also enabled hVIVO to open a dedicated outpatient unit to facilitate Phase II and Phase III trials including large-scale vaccine studies and respiratory studies.
At the beginning of 2025, the hVIVO Group acquired CRS, 2 clinical research units in Germany, adding to our capabilities to now include Phase I and II studies within the EU. Along with Venn Life Sciences, hVIVO’s consulting arm we are now a full-service early phase CRO and the world leaders in human challenge trials
At hVIVO, in late 2024 we completed a pilot hMPV characterisation trial, showing that we can produce a safe, measurable and reproducible disease in healthy volunteers, also demonstrating strong infection and symptomatic response rate, ready for clinical trials in H2 2025. Our Chief Scientific Officer recently presented the findings of this study at the 13th International RSV Symposium in Iguazu, Brazil with Nicolas Noulin presenting further data during the ESCMID conference.
On the back of this pilot study, we recently signed a contract with a new biopharmaceutical company to complete the final stage of the characterisation study, to expand the dataset and further strengthen our model. This is expected to commence in the first half of 2025, on pace for our goal of commencing human challenge trials in the second half of 2025.
Session type: 1-hour Oral Session
Session date: 13/04/2025
Session time and location: 16:15 in Hall 16
Session date: 12/04/2025
Session time and location : 12:00 - 13:30 in Poster Area in Hall D
Session date: 12/04/2025
Session time and location : 12:00 - 13:30 in Poster Area in Hall D
Session date: 12/04/2025
Session time and location : 12:00 - 13:30 in Poster Area in Hall D
Session date: 12/04/2025
Session time and location : 12:00 - 13:30 in Poster Area in Hall D
Session date: 12/04/2025
Session time and location : 12:00 - 13:30 in Poster Area in Hall D
